These statements are based on information available to us today August 8, 2012. We may not actually achieve our goals, carry out our plans or intentions or meet the expectations disclosed in our forward-looking statements and you should not place undue reliance on these statements. Actual results or events could differ materially. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions that we may enter into such as mergers, acquisitions, dispositions, joint ventures or any material agreement that we may enter into or terminate.
For additional information regarding the factors that could cause actual results to differ materially, please see the forward-looking statements section in today’s press release and the risk factors section of our most recent Form 10-Q, each of which were filed today with the SEC and are available on our website www.amarincorp.com. We encourage everyone to read these documents.
In addition please note that these remarks will contain non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure can be found within our second quarter financial results press release. Finally, an archive of this call will be posted to the Amarin website in the Investor Relations section.
I’ll now turn the call over to Joe Zakrzewski, Chairman and Chief Executive Officer of Amarin.Joseph S. Zakrzewski Thank you, Steve and welcome to everyone. I’m joined on this call today by Fred Ahlholm, our VP of Finance; Joe Kennedy, our General Counsel; and Steve Ketchum, Amarin’s President of R&D. On July 26, Amarin held a conference call regarding approval by FDA of our NDA for Vascepa. I hope that each of you had the opportunity to listen to that call. Because that call was so recent and included comments on a variety of topics beyond the NDA approval, I will keep today’s comments brief. Fred will then provide a financial results update and we’ll then take a few questions.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts